Clinical Trials Browser

Prostatic Neoplasms

Lung Neoplasms

Carcinoma, Transitional Cell

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Triple Negative Breast Neoplasms

Sarcoma, Kaposi

Squamous Cell Carcinoma of Head and Neck

Liposarcoma, Neoplasms, Sarcoma

Prostatic Neoplasms

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

Brain Neoplasms, Carcinoma, Renal Cell

Glioblastoma

Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

Prostatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Breast Neoplasms

Neoplasm Metastasis

Triple Negative Breast Neoplasms

Glioblastoma

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Colorectal Neoplasms

Colonic Neoplasms

Multiple Myeloma

Advanced Endometrial Cancer

First-line Non-small-cell Lung Cancer

Carcinoma, Transitional Cell

Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Transitional Cell

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Squamous Cell Carcinoma of Head and Neck

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Melanoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Skin Neoplasms

Endometrial Neoplasms

Multiple Myeloma

Clinical Trials

PEM-PRO

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

CheckCell-2

MK-5890-003

PULSAR

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

NeoSarc

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

PSMA Therapy and Immunotherapy in Kidney Cancer

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Abemaciclib + Pembrolizumab In Glioblastoma

PRIMUS006

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

TALON

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

MK-9999-01B

SOC-2320

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Pembrolizumab in Early Stage Colon Cancer

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

PELICAN

CARMA

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

AdvanTIG-306

AdvanTIG-211

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Sargramostim (GM-CSF) + PD-1

RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.